PatentsGlobal
Akebia Therapeutics Secures New U.S. Patent Extending Protection for Vafseo® (vadadustat) Through 2043
Akebia Therapeutics has obtained a new U.S. patent for Vafseo® (vadadustat), an oral treatment for anemia due to chronic kidney disease (CKD) in dialysis patients. Issued by the USPTO on November 17, 2026, the patent extends protection until January 18, 2043, and covers methods to modulate drug-drug interactions durin…
Wednesday, November 18, 2026